Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 2
2014 2
2015 1
2016 2
2018 3
2019 8
2020 4
2021 16
2022 18
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Antiviral Potential of Azelastine against Major Respiratory Viruses.
Fischhuber K, Bánki Z, Kimpel J, Kragl N, Rössler A, Bolze A, Muellauer B, Angerer J, Nagy G, Nagy E, Szijarto V. Fischhuber K, et al. Among authors: kimpel j. Viruses. 2023 Nov 23;15(12):2300. doi: 10.3390/v15122300. Viruses. 2023. PMID: 38140540 Free PMC article.
Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein.
Perdiguero B, Hauser A, Gómez CE, Peterhoff D, Sideris E, Sorzano CÓS, Wilmschen S, Schaber M, Stengel L, Asbach B, Ding S, Von Laer D, Levy Y, Pantaleo G, Kimpel J, Esteban M, Wagner R. Perdiguero B, et al. Among authors: kimpel j. Front Immunol. 2023 Nov 17;14:1270908. doi: 10.3389/fimmu.2023.1270908. eCollection 2023. Front Immunol. 2023. PMID: 38045703 Free PMC article.
Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera.
Mühlemann B, Wilks SH, Baracco L, Bekliz M, Carreño JM, Corman VM, Davis-Gardner ME, Dejnirattisai W, Diamond MS, Douek DC, Drosten C, Eckerle I, Edara VV, Ellis M, Fouchier RAM, Frieman M, Godbole S, Haagmans B, Halfmann PJ, Henry AR, Jones TC, Katzelnick LC, Kawaoka Y, Kimpel J, Krammer F, Lai L, Liu C, Lusvarghi S, Meyer B, Mongkolsapaya J, Montefiori DC, Mykytyn A, Netzl A, Pollett S, Rössler A, Screaton GR, Shen X, Sigal A, Simon V, Subramanian R, Supasa P, Suthar M, Türeli S, Wang W, Weiss CD, Smith DJ. Mühlemann B, et al. Among authors: kimpel j. bioRxiv [Preprint]. 2023 Sep 27:2023.09.27.559689. doi: 10.1101/2023.09.27.559689. bioRxiv. 2023. PMID: 37808679 Free PMC article. Preprint.
Retained avidity despite reduced cross-binding and cross-neutralizing antibody levels to Omicron after SARS-COV-2 wild-type infection or mRNA double vaccination.
Harthaller T, Falkensammer B, Bante D, Huber M, Schmitt M, Benainouna H, Rössler A, Fleischer V, von Laer D, Kimpel J, Würzner R, Borena W. Harthaller T, et al. Among authors: kimpel j. Front Immunol. 2023 Jul 21;14:1196988. doi: 10.3389/fimmu.2023.1196988. eCollection 2023. Front Immunol. 2023. PMID: 37545492 Free PMC article.
Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial.
Seekircher L, Bánki Z, Kimpel J, Rössler A, Schäfer H, Falkensammer B, Bante D, Forer L, Schönherr S; Shieldvacc-2 Study Group; Harthaller T, Sacher M, Ower C, Tschiderer L, Ulmer H, Krammer F, von Laer D, Borena W, Willeit P. Seekircher L, et al. Among authors: kimpel j. Lancet Microbe. 2023 Aug;4(8):e612-e621. doi: 10.1016/S2666-5247(23)00107-6. Epub 2023 Jun 21. Lancet Microbe. 2023. PMID: 37354911 Free PMC article. Clinical Trial.
67 results